E-viri
Odprti dostop
-
Martínez-Herrera, José Fabián; Sánchez Domínguez, Gisela; Juárez-Vignon Whaley, Juan J; Carrasco-Cara Chards, Sonia; López Vrátný, Claudia; Guzmán Casta, Jordi; Riera Sala, Rodrigo F; Alatorre-Alexander, Jorge A; Seidman Sorsby, Alec; Cruz Zermeño, Mayte; Conde Flores, Emilio; Flores-Mariñelarena, Rodrigo R; Sánchez-Ríos, Carla P; Martínez-Barrera, Luis M; Gerson-Cwilich, Raquel; Santillán-Doherty, Patricio; Jiménez López, José C; López Hernández, William; Rodríguez-Cid, Jerónimo R
Journal of thoracic disease, 01/2024, Letnik: 16, Številka: 1Journal Article
Lung cancer represents a significant global health concern, often diagnosed in its advanced stages. The advent of massive DNA sequencing has revolutionized the landscape of cancer treatment by enabling the identification of target mutations and the development of tailored therapeutic approaches. Unfortunately, access to DNA sequencing technology remains limited in many developing countries. In this context, we emphasize the critical importance of integrating this advanced technology into healthcare systems in developing nations to improve treatment outcomes. We conducted an analysis of electronic clinical records of patients with confirmed advanced non-small cell lung cancer (NSCLC) and a verified negative status for the epidermal growth factor receptor ( ) mutation. These patients underwent next-generation sequencing (NGS) for molecular analysis. We performed descriptive statistical analyses for each variable and conducted both univariate and multivariate statistical analyses to assess their impact on progression-free survival (PFS) and overall survival (OS). Additionally, we classified genetic mutations as actionable or non-actionable based on the European Society for Medical Oncology Scale of Clinical Actionability of Molecular Targets (ESCAT) guidelines. Our study included a total of 127 patients, revealing the presence of twenty-one distinct mutations. The most prevalent mutations were (18.9%) and Kirsten rat sarcoma viral oncogene homolog ( ) (15.7%). Notably, anaplastic lymphoma kinase ( ) hazard ratio (HR): 0.258, P<0.001, tumor mutation burden (TMB) (HR: 2.073, P=0.042) and brain magnetic resonance imaging (MRI) (HR: 0.470, P=0.032) demonstrated statistical significance in both the univariate and multivariate analyses with respect to PFS. In terms of OS, (HR: 0.285, P<0.001) and (HR: 0.482, P=0.024) exhibited statistical significance in both analyses. Applying the ESCAT classification system, we identified actionable genomic variations (ESCAT level-1), including , , breast cancer ( ) gene, c-ros oncogene 1 ( ), and rearranged during transfection ( ) gene, in 32.3% of the patients. Our findings from massive DNA sequencing underscore that 32.3% of patients who test negative for the mutation possess other targetable mutations, enabling them to receive personalized, targeted therapies at an earlier stage of their disease. Implementing massive DNA sequencing in developing countries is crucial to enhance survival rates among NSCLC patients and guide more effective treatment strategies.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.